FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387498617> ?p ?o ?g. }

• W4387498617 endingPage "56" @default.
• W4387498617 startingPage "48" @default.
• W4387498617 abstract "Aim. Evaluation of the efficacy and safety of human placenta hydrolyzate (HPH) Laennec in the treatment of non-alcoholic fatty liver disease (NAFLD) in an experimental and clinical study. Material and methods. An experimental study was carried out on NAFLD models reproducible by administering various doses of CCl4 to rats. The clinical study involved patients with NAFLD (n=60, mean age 47±9 years) who were on a standard diet of the military hospital of the Republic of Vietnam. Half of the patients (n=30) received Laennec (2 ml/day IM, 4 weeks), while the other half were in the control group. The collected results were analyzed by standard methods of mathematical statistics. Results. Studies in a preclinical model of NAFLD in rats showed a significant reduction in the progression of liver fibrosis against the background of improved lipid metabolism. No negative effects of HPH on the nervous, cardiovascular and respiratory systems of animals have been established. In a clinical study, the mean levels of liver dysfunction markers (AST, ALT, GGT) of patients with NAFLD at the time of treatment initiation in both groups were significantly higher than the normal range (AST - 111±12 U/l, ALT - 103±8 U/l, GGT - 462±60 IU/l). The use of Laennec led to a significant decrease in the incidence of NAFLD symptoms (fatigue, a feeling of bloating in the abdominal cavity, anorexia) and a decrease in the levels of AST, ALT, GGT after a day of the therapy week. After 2 weeks of HLP therapy, there was a significant decrease in the levels of AST (53±4 U/l, control: 99±14 U/l, P<0.001), ALT (71±6 U/l, control: 92±7 U/l, P<0.001) and GGT (260±21 IU/l, control: 384±74 U/l, P<0.001). After 4 weeks of treatment, the parameters significantly decreased towards the lower limit of the normal interval: AST - 45±4 U/l, ALT - 52±5 U/l, GGT - 191±19 IU/l (all P<0.05 compared with the values at 2nd week) against the background of the absence of positive dynamics in the levels of AST, ALT, GGT in the control group. The use of the drug did not cause statistically significant changes in the parameters of clinical or laboratory hematological examination, urinalysis results, levels of other liver enzymes, as well as vital signs. Multivariate analysis showed that the effects of HPH are practically independent of age, gender, medical history, initial levels of AST, ALT, GGT, and other parameters of the biochemical blood test of patients. Conclusion. HPH Laennec is an effective and safe monotherapy for NAFLD." @default.
• W4387498617 created "2023-10-11" @default.
• W4387498617 creator A5047830624 @default.
• W4387498617 creator A5080292376 @default.
• W4387498617 creator A5089345385 @default.
• W4387498617 date "2023-10-09" @default.
• W4387498617 modified "2023-10-12" @default.
• W4387498617 title "An open-label, controlled trial of the efficacy and safety of Laennec to improve liver function in patients with non-alcoholic fatty liver disease" @default.
• W4387498617 cites W1844843985 @default.
• W4387498617 cites W2107157268 @default.
• W4387498617 cites W2621939592 @default.
• W4387498617 cites W2788821298 @default.
• W4387498617 cites W2806839461 @default.
• W4387498617 cites W2810543027 @default.
• W4387498617 cites W2906945559 @default.
• W4387498617 cites W2999907367 @default.
• W4387498617 cites W3012883032 @default.
• W4387498617 cites W3029895132 @default.
• W4387498617 cites W3047246107 @default.
• W4387498617 cites W3111625382 @default.
• W4387498617 cites W3143409077 @default.
• W4387498617 cites W3178703016 @default.
• W4387498617 cites W4303615086 @default.
• W4387498617 doi "https://doi.org/10.31146/1682-8658-ecg-216-8-48-56" @default.
• W4387498617 hasPublicationYear "2023" @default.
• W4387498617 type Work @default.
• W4387498617 citedByCount "0" @default.
• W4387498617 crossrefType "journal-article" @default.
• W4387498617 hasAuthorship W4387498617A5047830624 @default.
• W4387498617 hasAuthorship W4387498617A5080292376 @default.
• W4387498617 hasAuthorship W4387498617A5089345385 @default.
• W4387498617 hasBestOaLocation W43874986171 @default.
• W4387498617 hasConcept C120665830 @default.
• W4387498617 hasConcept C121332964 @default.
• W4387498617 hasConcept C126322002 @default.
• W4387498617 hasConcept C2778654693 @default.
• W4387498617 hasConcept C2778772119 @default.
• W4387498617 hasConcept C2779134260 @default.
• W4387498617 hasConcept C2779478299 @default.
• W4387498617 hasConcept C2780559512 @default.
• W4387498617 hasConcept C2992208098 @default.
• W4387498617 hasConcept C512861765 @default.
• W4387498617 hasConcept C61511704 @default.
• W4387498617 hasConcept C71924100 @default.
• W4387498617 hasConcept C90924648 @default.
• W4387498617 hasConceptScore W4387498617C120665830 @default.
• W4387498617 hasConceptScore W4387498617C121332964 @default.
• W4387498617 hasConceptScore W4387498617C126322002 @default.
• W4387498617 hasConceptScore W4387498617C2778654693 @default.
• W4387498617 hasConceptScore W4387498617C2778772119 @default.
• W4387498617 hasConceptScore W4387498617C2779134260 @default.
• W4387498617 hasConceptScore W4387498617C2779478299 @default.
• W4387498617 hasConceptScore W4387498617C2780559512 @default.
• W4387498617 hasConceptScore W4387498617C2992208098 @default.
• W4387498617 hasConceptScore W4387498617C512861765 @default.
• W4387498617 hasConceptScore W4387498617C61511704 @default.
• W4387498617 hasConceptScore W4387498617C71924100 @default.
• W4387498617 hasConceptScore W4387498617C90924648 @default.
• W4387498617 hasIssue "8" @default.
• W4387498617 hasLocation W43874986171 @default.
• W4387498617 hasOpenAccess W4387498617 @default.
• W4387498617 hasPrimaryLocation W43874986171 @default.
• W4387498617 hasRelatedWork W1544002626 @default.
• W4387498617 hasRelatedWork W1606133142 @default.
• W4387498617 hasRelatedWork W1993700612 @default.
• W4387498617 hasRelatedWork W2067174853 @default.
• W4387498617 hasRelatedWork W2106991523 @default.
• W4387498617 hasRelatedWork W2171261870 @default.
• W4387498617 hasRelatedWork W2728735046 @default.
• W4387498617 hasRelatedWork W2905664713 @default.
• W4387498617 hasRelatedWork W4312776625 @default.
• W4387498617 hasRelatedWork W4313409935 @default.
• W4387498617 isParatext "false" @default.
• W4387498617 isRetracted "false" @default.
• W4387498617 workType "article" @default.